期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 288, 期 29, 页码 20868-20882出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M112.445734
关键词
-
资金
- National Institutes of Health [R01 NS074536, R01 NS056049]
- Korea Society of Ginseng
- National Research Foundation of Korea [2009-0072220]
- Ministry of Education, Science and Technology
- Samsung Biomedical Research Institute [B-A8-003]
- National Research Foundation of Korea [2009-0072220] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Amyloid beta-peptide (A beta) pathology is an invariant feature of Alzheimer disease, preceding any detectable clinical symptoms by more than a decade. To this end, we seek to identify agents that can reduce A beta levels in the brain via novel mechanisms. We found that (20S)-Rg3, a triterpene natural compound known as ginsenoside, reduced A beta levels in cultured primary neurons and in the brains of a mouse model of Alzheimer disease. The (20S)-Rg3 treatment induced a decrease in the association of presenilin 1 (PS1) fragments with lipid rafts where catalytic components of the gamma-secretase complex are enriched. The A beta-lowering activity of (20S)-Rg3 directly correlated with increased activity of phosphatidylinositol 4-kinase II alpha (PI4KII alpha), a lipid kinase that mediates the rate-limiting step in phosphatidylinositol 4,5-bisphosphate synthesis. PI4KII alpha overexpression recapitulated the effects of (20S)-Rg3, whereas reduced expression of PI4KII alpha abolished the A beta-reducing activity of (20S)-Rg3 in neurons. Our results substantiate an important role for PI4KII alpha and phosphoinositide modulation in gamma-secretase activity and A beta biogenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据